The posterchild for this success has been the use of monoclonal-antibody-based therapies targeting the PD1 receptor upregulated on activated T cells, or its ligands (programmed death ligands 1 and 2 (PD-L1 and PD-L2)), commonly upregulated by tumor and tumor-associated immune cells. The gene discussed is CD274; the disease is neoplasm.